Mechanistic studies show that CUDC-101 integrates HDAC and EGFR/HER2 pathway inhibition, blocks and inhibits MET- and AXL-mediated signaling, and reduces cancer cell migration [24, 48]. This evidence concerns the gene AXL and cancer.